Gepotidacin mesylate is under clinical development by GSK and currently in Phase III for Urinary Tract Infections. According to GlobalData, Phase III drugs for Urinary Tract Infections have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Gepotidacin mesylate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Gepotidacin mesylate overview

Gepotidacin mesylate (GSK-2140944) is under development for the treatment of uncomplicated urinary tract infection (acute cystitis) and Gram-negative bacterial infections like uncomplicated urogenital gonorrhea caused by neisseria gonorrhoeae and other bacterial infections. The drug candidate is administered orally as a capsule, tablet and intravenously as an infusion. It belongs to the bacterial topoisomerase type II, IV and DNA gyrase inhibitor (BTI) class of antibiotics. It is a new molecular entity. It was also under development for gram-positive acute bacterial skin and skin structure infections (ABSSSI), anthrax, plague and tularemia.

GSK overview

GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

For a complete picture of Gepotidacin mesylate’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.